6 Einträge gefunden

1. Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines.

   1. Wagenblast, Jens
   2. Baghi, Mehran
   3. Arnoldner, Christoph
   4. Bisdas, Sotirios
   5. Gstöttner, Wolfgang
   6. Ackermann, Hanns
   7. May, Angelika

   2009 - Forschungsinformationssystem des UKE
2. Effect of bortezomib and cetuximab in EGF-stimulated HNSCC.

   1. Wagenblast, Jens
   2. Baghi, Mehran
   3. Arnoldner, Christoph
   4. Bisdas, Sotirios
   5. Gstöttner, Wolfgang
   6. Ackermann, Hanns
   7. May, Angelika

   2008 - Forschungsinformationssystem des UKE
3. Effects of combination treatment of bortezomib and dexamethasone in SCCHN cell lines depend on tumor cell specificity.

   1. Wagenblast, Jens
   2. Baghi, Mehran
   3. Arnoldner, Christoph
   4. Bisdas, Sotirios
   5. Gstöttner, Wolfgang
   6. May, Angelika
   7. Knecht, Rainald

   2008 - Forschungsinformationssystem des UKE
4. A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN).

   1. Baghi, Mehran
   2. Hambek, Markus
   3. Wagenblast, Jens
   4. May, Angelika
   5. Gstoettner, Wolfgang
   6. Knecht, Rainald

   2006 - Forschungsinformationssystem des UKE
5. Adjuvant docetaxel, cisplatin and 5-fluorouracil (TPF) in locally advanced squamous cell carcinoma of the head and neck.

   1. Baghi, Mehran
   2. Hambek, Markus
   3. May, Angelika
   4. Radeloff, Andreas
   5. Gstoettner, Wolfgang
   6. Knecht, Rainald

   2006 - Forschungsinformationssystem des UKE
6. STAT 3 activation in head and neck squamous cell carcinomas is controlled by the EGFR.

   1. Hambek, Markus
   2. Baghi, Mehran
   3. Strebhardt, Klaus
   4. Strebhard, Klaus
   5. May, Angelika
   6. Adunka, Oliver
   7. Gstöttner, Wolfgang

   2004 - Forschungsinformationssystem des UKE